Summit Therapeutics SMMT
Valuation
Multiples measured against the stock's own five-year history
Around its usual level · 44th percentile, 5-year average -23.5x
Around its usual level · 40th percentile, 5-year average 31.0x
#5102 of 5338 stocks by PB (1 = cheapest)
Around its usual level · 55th percentile, 5-year average 32,526.4x
#5155 of 5161 stocks by PS (1 = cheapest)
P/E over five years
Dashed line is the 5-year average; the shaded band is one standard deviation either side.
Morningstar fair value estimate
| Multiple | Current | Forward | 5y average | Percentile vs. own history | Industry rank |
|---|---|---|---|---|---|
| PB | 14.09 | – | 30.97 | 40% (cheaper than usual) | #5102 of 5338 (1 = cheapest) |
| PE | -9.39 | -8.66 | -23.46 | 44% (cheaper than usual) | – |
| PS | 36,171.14 | 328.21 | 32,526.41 | 55% (pricier than usual) | #5155 of 5161 (1 = cheapest) |
Percentile is against this stock’s own 5-year valuation range: higher means it’s trading rich relative to its own history, lower means cheap relative to its own history — it is not a comparison against other companies. Forward multiples use consensus estimates for the next twelve months; a forward multiple below the current one usually signals analysts expect earnings to grow.
No comments yet — be the first to weigh in on SMMT.
Sign in to join the discussion.